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Variations in exposure to mitomycin C in an in vitro
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Summary The effect of mitomycin C on two human ovarian cancer cell lines was measured during several
exposure times and concentrations using the Human Tumour Colony-forming Assay (HTCA). Changes in
exposure time and concentration resulted in considerable differences in tumour cell survival. It is concluded
that several exposure times and concentrations are necessary for in vitro sensitivity testing. We suggest
alternative criteria derived from pharmacokinetic data in patients instead of one-tenth of the peak plasma
level which is the usual practice.
In vitro sensitivitiy testing of anticancer agents has
attracted much attention during the last two
decades. An important problem with any in vitro
system remains the reproduction of the in vivo drug
behaviour. In vivo drug behaviour can be
characterized by pharmacokinetic parameters such
as peak plasma concentration, concentration-time
product (or AUC), elimination half life, clearance
and volume(s) of distribution which, for the same
drug may vary considerably between patients (Slee
et al., 1983). The situation becomes even more
complex when the anticancer agent requires meta-
bolic activation, as this results in an even greater
interpatient variability.
For tumour cell lines colony-forming assays
appear to be the most reliable in vitro methods for
assessing the effect of drugs (Roper & Drewinko,
1976; Rupniak et al., 1983). For fresh tumour
material the in vitro double layer soft-agar assay, as
described by Hamburger and Salmon is most
frequently used (1977).
Usually, a concentration of one tenth of the peak
plasma level, as determined after systemic adminis-
tration to patients and an arbitrary one hour
exposure, is chosen for drug testing in the HTCA.
Sometimes 1/300 of the peak plasma level with a
continuous exposure is preferred (Alberts et al.,
1980; Bateman et al., 1980; Von Hoff et al., 1981;
Salmon et al., 1978). In several other studies the
exposure times have been varied more extensively
but only by large intervals and usually not in
relation to in vivo pharmacokinetic data (Calabro-
Jones et al., 1982; Jackson & Bender, 1979;
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Matsushima et al., 1985; Niell et al., 1982; Rupniak
et al., 1983).
In the present study the mean residence time,
based on moment analysis (Riegelman & Collier,
1980) is suggested as a more realistic exposure time.
The exposure time was varied according to the
range of mean residence times (MRT) determined
in patients after several routes of administration. As
the use of the in vitro double layer soft-agar assay
for sensitivity testing of fresh human tumour
specimens as described by Hamburger and Salmon
is subject to extensive discussion (Selby et al., 1983,
Slee et al., 1985), we have illustrated this approach
by the in vitro sensitivity testing to mitomycin C of
two human ovarian cancer cell lines. The in vitro
data are compared with in vivo pharmacokinetic
data reported for this drug.
Materials and Methods
Cell lines
Two cell lines denoted as C-Ov-362 and C-Ov-318
were derived from fresh specimens of pleural and
ascites aspirates from ovarian cancer patients. A
few colonies grown in the HTCA were transferred
from a Petri dish to a monolayer culture; both cell
lines were tested between the 15th and 20th
passage. The monolayer cultures were treated with
a 0.1% trypsin solution. Subsequently the material
was centrifuged for 5 min at 600rpm, and washed
in Dulbecco's MEM and 10% newborn calf serum
(NBCS). The cell suspension was then pushed
through 21, 23 and 25 gauge needles.
Drug exposure in the HTCA
A fresh solution of the i.v. formulation of MMC
was prepared in 0.9% saline solution. Tumour cells
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were transferred to tubes and incubated with MMC
in Hank's Balanced Salt Solution (HBSS) and 10%
foetal calf serum (FCS), while shaking in a 37°C
water bath. For each time an untreated control was
incubated. After drug exposure the drug containing
media were decanted and before plating the cells
were washed twice in Dulbecco's MEM and 10%
NBCS by centrifugation for 5min at 600rpm.
During incubation and culture the cells were kept
in the dark because of possible light inactivation of
MMC.
The concentrations of MMC following different
exposure times were determined by HPLC with on-
line ultraviolet and electrochemical detection:
MMC appeared to be stable for at least several
hours (Hoogvliet, 1985).
for in vitro drug exposure. These 'areas under the
curves' are defined as the product of concentration
and exposure time and expressed in Mgml1 mmin.
Results
Culture data
Inspection on day 1 of all dishes of cell line C-Ov-
362 showed a (near) single cell suspension: 99%
single cells and 1% duplets were present. With cell
line C-Ov-318 95% single cells and 5% duplets
were seen. In both cell lines no aggregates were
detected. Maximum growth was reached at 19-21
days and for all experiments the plating efficiency
varied from 5.7 to 6.0%.
Human tumour colony-forming assay
All assays were carried out using the HTCA
described by Hamburger and Salmon (1977) with
some modifications. The following changes were
introduced: an identical standard medium was
prepared for bottom and top layer on the day of
plating. Dimercaptoethanol, DEAE-dextran, con-
ditioned medium and CaCl2 were omitted from the
medium. Heparin free ascites-fluid from a patient
with an ovarian cancer was centrifuged. The cell-
free supernatant was inactivated at 50°C for 30min
and used after storage at -20°C. The medium was
enriched with 25% of this cell-free ascites fluid
(Slee et al., 1985). The medium was warmed in a
37°C water bath. The underlayer consisted of 1 ml
of the standard medium in 0.5% agar plated on
35 x 10mm Petri dishes. The top layer consisted of
1 ml of the standard medium in 0.3% agar and
contained a suspension of 5 x 104 cells. Details of
this slightly modified technique have been described
elsewhere (Slee et al., 1985). Plating was carried out
in duplicate. Before plating, cells were exposed for
different periods to MMC concentrations of 100,
250 and 500ngml-1; each concentration for 30, 60,
90, 120 and 180min. The Petri dishes were kept for
3 weeks in a humidified* incubator at 37°C, 5%
CO2 and 95% air. On day 1 the dishes were
examined with an inverted microscope for possible
aggregates of 10 or more cells. Plates were
examined for colony formation after 21 days of
incubation. A colony was defined as a group of
more than 30 cells. Per cent survival was calculated
by dividing the mean number of colonies in the
treated sample by the mean number in the coherent
untreated control sample and multiplying by 100.
In vitro AUC
Simultaneous variation of exposure time and con-
centration results in several 'areas under the curves'
Sensitivity data
For both cell lines the influence of the exposure
time and concentration of MMC on the tumour cell
survival in the HTCA is depicted in figure 1.
Exposure during 30min with 100ngml 1 MMC did
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Figure 1 Relation between colony survival in the
HTCA (in percentages) and exposure time at different
concentrations (O>2 K=100ngml-', 0 O=
250ngml- 1 and 0 *= =500ngml-1). a: cell line
C-Ov-362, b: cell line C-Ov-318.VARYING EXPOSURE TO MITOMYCIN C IN A COLONY-FORMING ASSAY 953
survival and for cell line C-Ov-318 it even resulted
in an increase in survival, a phenomenon which has
been reported before (Selby et al., 1983).,Exposure
during 120-180min with a concentration of
500ngml-1 led to almost complete inhibition of
colony growth in both cell lines. The difference
between the responsiveness of both cell lines at
higher concentrations and identical exposure times
is clear from the data in figure 1, C-Ov-362 being
more responsive to MMC than C-Ov-318. The
differences between the responsiveness of both cell
lines at increasing exposure times and identical
concentrations is shown in Figure 2. The figures
illustrate that the steepness of the concentration-
response curve also depends on the applied
exposure time.
In vitro AUC
For both cell lines the in vitro AUC was related to
the percentage survival in the HTCA. Survival in
vitro appeared to be linearly related with log in
vitro AUC for C-Ov-362 (c.c.= -0.97 for n=11)
and for C-Ov-318 (c.c. = -0.88 for n= 13) (Figure
3). The effect of exposure time and exposure con-
centration on the survival of C-Ov-362 cells in
particular was more or less directly related:
doubling of the exposure time allowed halving of
the concentration as can be seen in Table I. An
AUC of 15, 30 and 45jigml-1 min was achieved in
two ways but colony growth inhibition was very
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Figure 2 Relation between colony survival in the
HTCA and concentration of MMC after several
exposure times (O> O> =30min, O O =60min,
E OJ=90min, 0*=120min, * *=
180min). a: cell line C-Ov-362, b: cell line C-Ov-318.
Figure 3 Relation between colony survival in the
HTCA and in vitro AUC for cell line C-Ov-362 (0)
and C-Ov-318 (0); c.c. =-0.97 (C-Ov-362, n=11),
c.c. -0.89 (C-Ov-318, n= 13).
Table I Data on exposure conditions and survival in two
ovarian cancer cell lines
Exposure Concen- Survival (%)
time tration AUC
(min) (ngml-) jgml-min C-Ov-362 C-Ov-318
30 100 3 99 + 1.6 121
60 100 6 60.7+ 8.2 78
90 100 9 55.5+ 6.5 66
120 100 12 38 + 9.3 85
180 100 18 25.7+ 8.2 57
30 250 7.5 67.6+ 6.6 66
60 250 15 32 + 7.9 75
90 250 22.5 26.5+ 4.5 56
120 250 30 10.3+ 4.6 55
180 250 45 3.7+ 1.7 26
30 500 15 26.7+ 10.4 60
60 500 30 7.2+ 4.9 35
90 500 45 5 + 0 20
120 500 60 1 + 0.8 7
180 500 90 0 + 0 nd
The AUCs of C-Ov-362 were significantly
different from those of C-Ov-318 at identical per-
centages survival (paired Student's t-test: P<0.005).
The AUC which resulted in a complete inhibition
of colony growth was 57jgml-1 min for C-Ov-362
and 1 6pgml-1 min for C-Ov-318.
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Reproducibility
Experiments with C-Ov-362 were carried out 3
times at intervals of 2 months to study the repro-
ducibility of the HTCA for these cell lines. The
standard deviation of the percentage survival of all
treated cultures ranged up to 10.4% survival; the
mean standard deviation was 5.0+3.4%.
Discussion
Human tumour colony-forming assays have been
suggested for sensitivity testing of anticancer agents.
One of the criticisms of this in vitro testing is that
exposure times and concentrations which mimic
drug behaviour in individual patients are not
sufficiently taken into account. As problems with
sensitivity testing as applied to fresh human tumour
specimens are frequently stressed, the influence of
exposure time and concentration was studied in cell
lines.
Two human ovarian cancer cell lines were
exposed for several periods of time over a range of
concentrations of mitomycin C. The effect on
colony-forming tumour cells was studied with the
HTCA. Increasing drug concentrations resulted in
decreasing tumour cell survival (Figures 1 and 2).
Not only the drug concentration, but also the
exposure time was important for in vitro sensitivity
testing. Small changes in exposure times resulted in
a clear decrease of cell survival. By using the in
vitro AUC which is the product of concentration
and exposure time, the effect of both factors on cell
survival was taken into account. The in vitro AUCs
resulted in significantly different percentages of cell
survival for both cell lines. The two cell lines were
sensitive in vitro according to the sensitivity criteria
given in the literature: one tenth of the peak plasma
levels of MMC concentration of 1.0 gml- during
1 h (or 60pgml-1min) resulted in less than 30%
cell survival (Alberts et al., 1981).
Pharmacokinetic data as measured in patients'
plasma, vascular perfusion of a tumour and
diffusion within the tumour determine the
pharmacodynamic effect of a drug on the tumour
cells. Although the principal parameters for this
effect are the concentration of the drug at the
tumour site (the target) and the duration of time
that the concentration is maintained there, we used
plasma pharmacokinetic data of MMC as a
guideline for in vitro sensitivity testing as no data
are available on concentrations at the target. In
several publications pharmacokinetic data on MMC
measured in plasma are given (den Hartigh et al.,
1983; van Oosterom et al., 1984). The AUCs after
i.v. administration of doses of 6-20mgm2, varied
from 6.5 to 17.2pgml-1 min (n= 16) (den Hartigh
et al., 1983; van Oosterom et al., 1984). When
complete inhibition of cell survival is considered
predictive of responsiveness in patients, the in vitro
AUCs (48 and 116pgml- min) are in the high
range when compared to plasma pharmacokinetic
data. In clinical studies a tumour is supposed to be
sensitive in vitro when less than 30% survival is
obtained after drug exposure (Alberts et al., 1981).
The in vitro AUC which gave rise to less than 30%
survival was 18 and 42pgml-1min for C-Ov-362
and C-Ov-318 respectively. These in vitro AUCs are
also in the high range compared to the AUCs
determined after i.v. administration.
In our opinion, it is not the plasma concentration
alone which should be the criterion for in vitro
sensitivity testing but also the in vivo exposure time
of tissues (in particular the tumour) to the drug.
The in vivo mean residence time is considered to be
the composite of all pharmacokinetic processes
taking place in patients after drug treatment. One
report gives the MRT of MMC (de Bruijn et al.,
1986). After i.v. administration of a dose of
20mgm 2 the MRT was 77.5+7.8min. Based on
these data a wide range of exposure times was
chosen for in vitro exposure: 30-180min, in the
present study.
The experiments with C-Ov-362 in the HTCA
were repeated three times at intervals of at least
two months. The mean standard deviation of
percentage colony survival was 5.0+3.4%. This low
standard deviation indicates a good reproducibility
of the assay for this cell line.
In view of the fact that the pharmacokinetic
parameters vary from one patient to another and
variation in concentration and exposure time results
in changes in cell survival, it is necessary to vary
both parametets in vitro. To combine these two
parameters we have introduced the in vitro AUC.
This helps to achieve a more realistic reproduction
of in vivo drug behaviour and the predictive
accuracy for the in vitro system may therefore be
increased. Based on our observations it can be
concluded that the predictive accuracy of in vitro
tests carried out with only one concentration and
one exposure time for a drug will be low.
Another consequence of our observations is to
enlarge the AUC in patients by increasing the
exposure time and/or the concentration at the
tumour. Iv. administration of a higher dose implies
an increased risk of toxicity and therefore, this can
only be achieved by non-systemic administrations.
A suitable example is human ovarian cancer which
is usually confined to the peritoneal cavity. With
intraperitoneal administration of MMC a larger in
vivo AUC is achieved in the peritoneal cavity which
approximates more closely to the range which
results in less than 30% colony survival in theVARYING EXPOSURE TO MITOMYCIN C IN A COLONY-FORMING ASSAY 955
HTCA. Preliminary experiments in a group of 20
patients who were treated intraperitoneally for
relapsing ovarian cancer support this view; a 50%
response rate has been achieved (van Oosterom et
al., to be published).
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